A pilot study on the motor effects of rimantadine in Parkinson's disease

Virgilio Gerald H Evidente, Charles Howard Adler, John Nathaniel Caviness, Katrina Gwinn-Hardy

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The purpose of this pilot study was to determine whether rimantadine, the alpha-methyl derivative of amantadine, might have any antiparkinsonian properties. In an open-label trial, 14 patients (12 de novo and 2 on levodopa treatment) with Hoehn and Yahr stage 2 to 3 Parkinson's disease were placed on rimantadine at doses of 100 to 300 mg/d. No patients had dyskinesias or motor fluctuations. Ten of 14 (71%) reported a mean subjective response of 33% (range 10%-60%) to rimantadine. After treatment, there was a 13% improvement in Hoehn and Yahr staging (p = .01) and a 20% improvement in mean motor Unified Parkinsons Disease Rating Scale scores (p = .02). Rigidity was the most consistently improved feature among the responders. Mean effective dose was 256 mg/d (range 200-300 mg/d). Side effects were mild and transient, with nausea being most common (4/14). We conclude that rimantadine has some motor benefits in Parkinson's disease. A double-blind placebo-controlled study is warranted to validate our findings.

Original languageEnglish (US)
Pages (from-to)30-32
Number of pages3
JournalClinical Neuropharmacology
Volume22
Issue number1
StatePublished - Jan 1999

Fingerprint

Rimantadine
Parkinson Disease
Antiparkinson Agents
Amantadine
Dyskinesias
Levodopa
Nausea
Placebos
Therapeutics

Keywords

  • Amantadine
  • Parkinson's disease
  • Rimantadine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

A pilot study on the motor effects of rimantadine in Parkinson's disease. / Evidente, Virgilio Gerald H; Adler, Charles Howard; Caviness, John Nathaniel; Gwinn-Hardy, Katrina.

In: Clinical Neuropharmacology, Vol. 22, No. 1, 01.1999, p. 30-32.

Research output: Contribution to journalArticle

@article{803c4875bdfe4814a764a089e9d627d1,
title = "A pilot study on the motor effects of rimantadine in Parkinson's disease",
abstract = "The purpose of this pilot study was to determine whether rimantadine, the alpha-methyl derivative of amantadine, might have any antiparkinsonian properties. In an open-label trial, 14 patients (12 de novo and 2 on levodopa treatment) with Hoehn and Yahr stage 2 to 3 Parkinson's disease were placed on rimantadine at doses of 100 to 300 mg/d. No patients had dyskinesias or motor fluctuations. Ten of 14 (71{\%}) reported a mean subjective response of 33{\%} (range 10{\%}-60{\%}) to rimantadine. After treatment, there was a 13{\%} improvement in Hoehn and Yahr staging (p = .01) and a 20{\%} improvement in mean motor Unified Parkinsons Disease Rating Scale scores (p = .02). Rigidity was the most consistently improved feature among the responders. Mean effective dose was 256 mg/d (range 200-300 mg/d). Side effects were mild and transient, with nausea being most common (4/14). We conclude that rimantadine has some motor benefits in Parkinson's disease. A double-blind placebo-controlled study is warranted to validate our findings.",
keywords = "Amantadine, Parkinson's disease, Rimantadine",
author = "Evidente, {Virgilio Gerald H} and Adler, {Charles Howard} and Caviness, {John Nathaniel} and Katrina Gwinn-Hardy",
year = "1999",
month = "1",
language = "English (US)",
volume = "22",
pages = "30--32",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A pilot study on the motor effects of rimantadine in Parkinson's disease

AU - Evidente, Virgilio Gerald H

AU - Adler, Charles Howard

AU - Caviness, John Nathaniel

AU - Gwinn-Hardy, Katrina

PY - 1999/1

Y1 - 1999/1

N2 - The purpose of this pilot study was to determine whether rimantadine, the alpha-methyl derivative of amantadine, might have any antiparkinsonian properties. In an open-label trial, 14 patients (12 de novo and 2 on levodopa treatment) with Hoehn and Yahr stage 2 to 3 Parkinson's disease were placed on rimantadine at doses of 100 to 300 mg/d. No patients had dyskinesias or motor fluctuations. Ten of 14 (71%) reported a mean subjective response of 33% (range 10%-60%) to rimantadine. After treatment, there was a 13% improvement in Hoehn and Yahr staging (p = .01) and a 20% improvement in mean motor Unified Parkinsons Disease Rating Scale scores (p = .02). Rigidity was the most consistently improved feature among the responders. Mean effective dose was 256 mg/d (range 200-300 mg/d). Side effects were mild and transient, with nausea being most common (4/14). We conclude that rimantadine has some motor benefits in Parkinson's disease. A double-blind placebo-controlled study is warranted to validate our findings.

AB - The purpose of this pilot study was to determine whether rimantadine, the alpha-methyl derivative of amantadine, might have any antiparkinsonian properties. In an open-label trial, 14 patients (12 de novo and 2 on levodopa treatment) with Hoehn and Yahr stage 2 to 3 Parkinson's disease were placed on rimantadine at doses of 100 to 300 mg/d. No patients had dyskinesias or motor fluctuations. Ten of 14 (71%) reported a mean subjective response of 33% (range 10%-60%) to rimantadine. After treatment, there was a 13% improvement in Hoehn and Yahr staging (p = .01) and a 20% improvement in mean motor Unified Parkinsons Disease Rating Scale scores (p = .02). Rigidity was the most consistently improved feature among the responders. Mean effective dose was 256 mg/d (range 200-300 mg/d). Side effects were mild and transient, with nausea being most common (4/14). We conclude that rimantadine has some motor benefits in Parkinson's disease. A double-blind placebo-controlled study is warranted to validate our findings.

KW - Amantadine

KW - Parkinson's disease

KW - Rimantadine

UR - http://www.scopus.com/inward/record.url?scp=0032904035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032904035&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 30

EP - 32

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 1

ER -